Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

HROWM - Harrow Inc - 11.875% NT REDEEM 31/12/2027 USD 25


Previous close
26.24
0   0%

Share volume: 3,023
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$26.24
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-1.58%
1 Month
1.05%
3 Months
1.15%
6 Months
6.01%
1 Year
12.68%
2 Year
27.30%
Key data
Stock price
$26.24
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$20.85 - $26.65
52 WEEK CHANGE
$0.13
MARKET CAP 
1.436 B
YIELD 
10.91%
SHARES OUTSTANDING 
35.483 M
DIVIDEND
$0.7422
EX-DIVIDEND DATE
07/15/2024
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,694
AVERAGE 30 VOLUME 
$3,670
Company detail
CEO:
Region: US
Website: harrowinc.com
Employees: 22
IPO year: -
Issue type:
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas

Recent news